Clinical Trial

A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis

Study acronym: INT-210-II102
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Multicenter, Randomized, Open-label Clinical Study to Evaluate the Safety and Efficacy of INT-210 Capsules in Participants with Active Ulcerative Colitis. The study aims to evaluate the safety, efficacy, pharmacokinetic (PK) characteristics, pharmacodynamic (PD) characteristics of INT-210 in participants with active ulcerative colitis (UC).
Trial Details
NCT Number NCT07692165
Lead Sponsor Innatus Therapeutics (Shanghai) Co., Ltd.
Conditions Ulcerative Colitis (UC)
Enrollment 24 participants
Start Date 2026-06-11
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-09